12 results about "Immunodeficiency disease" patented technology

The invention relates to an anti-CD28 antibody or an antigen binding fragment thereof, and a multispecific antibody constructed based on the antibody or the antigen binding fragment thereof, such as an anti-CD3 * CD28 bispecific antibody and an anti-tumor associated antigen (TAA) * CD3 * CD28 trispecific antibody. The invention also relates to a nucleic acid molecule encoding the antibody or the antigen binding fragment thereof, a vector and a cell comprising the nucleic acid molecule, a pharmaceutical composition comprising the antibody or the antigen binding fragment thereof, and application of the antibody or the antigen binding fragment thereof, especially application of the antibody or the antigen binding fragment thereof in treating tumors or immunodeficiency diseases.

Provided are an anti-CD28 antibody or an antigen-binding fragment thereof, and a multi-specific antibody constructed on the basis of the antibody or the antigen-binding fragment thereof. The multi-specific antibody comprises an anti-CD3×CD28 bispecific antibody and an anti-tumor-associated antigen (TAA)×CD3×CD28 trispecific antibody. Further provided are a nucleic acid molecule encoding the antibody or the antigen-binding fragment thereof, a vector and a cell comprising the nucleic acid molecule, a pharmaceutical composition comprising the antibody or the antigen-binding fragment thereof, and the use of the antibody or the antigen-binding fragment thereof, in particular for the treatment of tumors or immunodeficiency diseases.

Camptothecin analogs of formula (I), (II), (III) are described, as well as conjugates comprising these camptothecin analogs. These camptothecin analogs and conjugates are useful as therapeutic agents, particularly for the treatment of cancer, infectious diseases, inflammatory diseases, autoimmune diseases, and immunodeficiency diseases.

This invention relates to 2-amino-4-methylquinazoline compounds, their preparation methods, uses, and pharmaceutical compositions. Specifically, it provides a compound represented by Formula I, which is a phosphatidylinositol 3-kinase δ (PI3Kδ) inhibitor that can be used to prevent and / or treat diseases related to PI3Kδ activity, such as tumors, autoimmune diseases, immunodeficiency diseases, inflammation, kidney diseases, cardiovascular diseases, metabolic / endocrine disorders, or neurological diseases.

This invention relates to an IRAK4 degrading agent and its uses. This degrading agent can be used to treat or prevent diseases such as cancer, neurodegenerative diseases, viral diseases, autoimmune diseases, inflammatory diseases, hereditary diseases, hormone-related diseases, metabolic diseases, organ transplant-related diseases, immunodeficiency diseases, destructive bone diseases, proliferative diseases, infectious diseases, cell death-related conditions, thrombin-induced platelet aggregation, liver diseases, pathological immune conditions involving T cell activation, cardiovascular diseases, or CNS diseases.

The invention relates to a targeted protein degradation compound as well as a preparation method and application thereof, and belongs to the field of medicines. Specifically, the invention relates to a compound as shown in a general formula (I), a preparation method thereof and a pharmaceutical composition containing the compound, the invention also relates to the application of the compound in preparation of medicines for treating or preventing autoimmune diseases, inflammatory diseases, cancers, viral diseases, neurodegenerative diseases, hereditary diseases, hormone-related diseases, metabolic diseases, organ transplantation-related diseases, immunodeficiency diseases, destructive bone diseases, proliferative diseases, infectious diseases and the like. The invention also relates to the application of the medicine for treating diseases related to cell death or cardiovascular diseases. Wherein each substituent in the general formula (I) is as defined in the specification. B-L-K (I)

IPEX (Immune dysregulation Polyendocrinopathy X linked) syndrome is a primary immunodeficiency caused by mutations in the gene encoding the transcription factor forkhead box P3 (FOXP3), which leads to the loss of function of thymus-derived CD4+CD25+ regulatory T (tTreg) cells. Preclinical and clinical studies suggest that T cell gene therapy approaches designed to selectively restore the repertoire of Treg cells by transfer of wild type FOXP3 gene is a promising potential cure for IPEX. However, there is still a need for a vector that can be used efficiently for the preparation of said Treg cells. The inventors thus compared 6 different lentiviral constructs according to 4 criteria (vector titers, level of transduction of human CD4+ T cells, level of expression of FOXP3 and ΔLNGFR genes, degree of correlation between both expression) and selected one construct comprising a bidirectional PGK-EF1a promoter that showed remarkable efficiency.

This invention belongs to the field of pharmaceutical technology and relates to thienopyrimidine derivatives, their preparation methods, uses, and pharmaceutical compositions. The thienopyrimidine derivatives, as shown in formula (I), are phosphatidylinositol 3-kinase δ (PI3Kδ) inhibitors and can be used to prevent and / or treat diseases related to PI3Kδ activity, such as tumors, autoimmune diseases, immunodeficiency diseases, kidney diseases, cardiovascular diseases, inflammation, metabolic / endocrine dysfunction, or neurological diseases.

The invention relates to an IRAK4 degradation agent and application thereof. The degrading agent can be used for treating or preventing cancer, neurodegenerative diseases, viral diseases, autoimmune diseases, inflammatory diseases, hereditary diseases, hormone-related diseases, metabolic diseases, diseases related to organ transplantation, immunodeficiency diseases, destructive bone diseases, proliferative diseases, infectious diseases, conditions related to cell death, and the like. Thrombin-induced platelet aggregation, liver diseases, pathological immune conditions involving T cell activation, cardiovascular diseases or CNS diseases, etc.

The present disclosure provides methods for predicting the clinical response to therapy of a subject with an autoimmune disease or disorder and / or predicting the prognosis of a subject with an immune deficiency (e.g., leukemia) based on characterizing the subject's B cell immune repertoire. In one embodiment, the method provides for determining the frequency of class switch recombination and / or somatic hypermutation of the B cell receptor repertoire in a pre-treatment sample and predicting the subject's prognosis and / or response to therapy based on the measured frequency of class switching and / or somatic hypermutation. In another embodiment, the method provides for treating the subject based on determining the frequency of immune receptor class switching and / or somatic hypermutation and the resulting prediction of prognosis and / or response to therapy based on the measured frequency of class switching and / or somatic hypermutation.

This invention relates to the application of asparagine in the preparation of antiviral drugs and / or drugs for treating immunodeficiency diseases, belonging to the field of biomedical technology. This invention is the first to discover that asparagine can induce TBK1 activation, increasing the expression of type I interferon in the body under viral infection conditions, enabling the body to rapidly respond to host defense mechanisms and enhance immunity when subjected to viral infection, thereby achieving a broad-spectrum antiviral effect. It also discloses a new use of asparagine as a TBK1 agonist, which can be used in the preparation of antiviral drugs, drugs for treating immunodeficiency diseases, and products for enhancing immunity. Furthermore, asparagine is a non-essential amino acid for the human body, possessing characteristics such as being green, safe, and environmentally friendly; it can be used as a functional additive in pharmaceuticals, health products, or food products.

The invention relates to application of asparagine in preparation of antiviral infection drugs and / or immunodeficiency disease treatment drugs, and belongs to the technical field of biological medicines. It is found for the first time that asparagine can induce activation of TBK1 and improve the expression quantity of I-type interferon of an organism under the virus infection condition, so that when the organism is subjected to virus infection, a host defense mechanism is rapidly responded, the immunity is improved, and then the broad-spectrum virus infection resisting effect is achieved. Meanwhile, the invention discloses new application of asparagine as the TBK1 agonist, and asparagine can be used for preparing antiviral infection drugs, drugs for treating immunodeficiency diseases and products for improving immunity. The asparagine belongs to a non-essential amino acid of a human body, has the characteristics of being green, safe, environment-friendly and the like, and is applied to products such as medicines, health-care products or foods as a functional additive.